The Catherine Elizabeth Blair Memorial Foundation supports innovative neuroblastoma research in institutions across the US and internationally.  

 

May 2025: $25,000 grant to Dr. Kelly Goldsmith and Dr. Thomas Cash of Emory University for ANBL2131: A Children’s Oncology Group (COG) Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma. This Phase 3 clinical trial adds chemoimmunotherapy to the Induction phase of treatment for high-risk patients. 

​​​​

DECEMBER 2023: $25,000 grant to Dr. Anthony Sandler at Children's National for "Transforming Care for Children with Neuroblastoma," to help further Dr. Sandler's ongoing immunotherapy research as it nears the clinical trial phase. 

​

Update 9/24 Click here to read an update on this research:

August 2023: $25,000 grant in partnership with the Alex's Lemonade Stand Foundation for "Drugging MYCN," a project to develop targeted drugs for the MYCN protein.  The multi-disciplinary research team is led by Yael Mosse at Children's Hospital of Philadelphia.  

​

Update 8/23 Click here to read an update on this research: 

December 2022: $25,000 grant to Dr. Anthony Sandler at Children's National for "Driving Towards a Novel Neuroblastoma Clinical Trial." After FDA and review board approval, the research we have been funding for years will begin recruiting for a clinical trial. 

​

Update 7/22 Click here to read an update on this research:

December 2021: $36,000 grant to Dr. Kelly Goldsmith and Dr. Thomas Cash at Emory University in Atlanta for NANT 2017-01, A Phase 1 Study of 131 I-MIBG with Dinutuximab +/- Vorinostat for Relapsed/Refractory Neuroblastoma. This ongoing study is looking at MIBG treatment in combination with a monoclonal antibody, Dinutuximab.  

​

Update 8/22 Click here to read an update on this research:

 November 2021: $25,000 grant to Dr. Anthony Sandler at Children's National for "Accelerating Research Towards Neuroblastoma Treatments" - the translational stage is the final step before a clinical trial of the cell vaccine.

​

Update 10/21 Click here to read an update on this research:

Update 3/21  Click here to read a press release about this grant:

December 2020: $25,000 grant to Dr. Anthony Sandler at Children's National for "Moving the Dial on Neuroblastoma Research and Treatment" - continuing the team's vaccine research, moving towards clinical trials.

​

$100,000 in grants: Advancing Breakthroughs in Neuroblastoma Research and Care: Each year from 2015-2019 we granted $25,000 to Dr. Anthony Sandler's research lab at Children's National in Washington, DC for his work on immune-based tumor vaccine therapy.  

​

$25,000 Grant: Fully Human Glypican-2 Targeting Bispecifics for the Treatment of Neuroblastoma: In 2018, we granted $25,000 to Dr. Colin Correnti at the Fred Hutchinson Cancer Research Institute in Seattle, with key collaborator Julie Park, MD at Seattle Children's Hospital for an immunotherapy project creating clinic-ready antibodies to be used in future research.  

​

$20,000 Grant: Phase I/II Clinical Trial for Neuroblastoma with ALK Mutations: In 2016, we granted $20,000 in collaboration with a multi-charity group brought together by Solving Kids' Cancer to open a multi-institution trial of a tumor-inhibiting drug driven by ALK mutations.